Page 1 of 3

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT					ATTY. DOCKET NO.8524-71226 APPLICATION NO. 08/807,506								
					APPLICANTS SMIT et al.								
						LING DATE		GROUP 1648					
				U.S. 1	PATE	NT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT No.		MENT No. DATE		NAME		ASS	SUB- CLASS	FII	ING DATE		
	AA1	5,20	06,344	Apr. 27, 1993		Katre et al.		0	351	Jar	1. 11, 1988		
				FOREIGN	PA:	TENT DOCUMENTS			· 				
EXAMINER INITIAL		DOCU	MENT No.	DATE COU		OUNTRY		ASS	SUB-CI	ASS	TRANSLATION		
		0 154 316		EP		,			<u> </u>				
			THER (Incl	uding Author,	Tit	le, Date, Pertinent Pag	es,	etc.)					
AB			Glycol Inc	Katre et al., Chemical Modification of recombinant Iterleukin 2 by Polyethylene Glycol Increases its Potency in the Murine Meth A Sarcoma Model, Proc. Natl. Acad. Sci., Vol. 84, pp. 1487-1491, March 1987.									
MB			Mass Mapp Laser Desc	Liao et al., An Approach to Locate Phosphorylation Sites in a Phosphoprotein: Mass Mapping by Combining Specific Enzymatic Degradation with Matrix-Assisted Laser Desorption/lonization Mass Spectrometry, Analytical Biochemistry 219, pp. 9-20 (1994).									
AB .			Modificati	Suckau et al., Protein Surface Topology-probing by Selective Chemical Modification and Mass Spectrometric Peptide Mapping, Proc. Natl. Acad. Sci., Vol. 89, pp. 5630-5634, June 1992.									
B			Caccia et al., Stabilization of Recombinant Human Basic Fibroblast Growth Factor by Chemical Modifications of Cysteine Residues, Eur. J. Biochem, 204, pp. 649-655 (1992).										
AB			Lokker et al., Structure-Activity Relationship Study of Human Interleukin-3, The Journal of Biological Chemistry, Vol. 266, No. 16, Issue of June 5, pp. 10624-10631, (1991).										
AB			Katre, Immunogenicity of Recombinant IL-2 Modified by Covalent Attachment Polyethylene Glycol, The Journal of Immunology, Vol. 144, No. 1, pp. 209-213, January 1, 1990.										
EVANTNED						<u> </u>	DATE	CONSI	DERED	111	12/08		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw licitation if not in conformance and not considered. Include copy of this form with next communication to Appl

EXAMINER

									•						
<u>.</u>								,			Page 2 of 3				
FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT					PΙ	ATTY. DOCKET NO.8524-71226			APPLICATION NO. 08/807,506						
					APPLICANTS SMIT et al.										
						FILING DATE February 27, 1997			GROUP 1648						
								L			·				
	···			v.s.	PATE	NT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT No.		DATE		NAME CL		ASS SUB- CLASS	FILING DATE						
	AA1														
				FOREIG	N PA	TENT DOCUMENTS	 								
EXAMINER INITIAL		DOCUMENT No.		DOCUMENT No.		DOCUMENT No. DA		DATE	COU	COUNTRY		ASS	SUB-CL	ASS	TRANSLATION
		<u> </u>			<u> </u>	· · · · · · · · · · · · · · · · · · ·									
	1	- 1	OTHER (Incl	uding Author,	Tit	le, Date, Pertine	nt Pages,	etc.)							
AB			Domain, Bi	Smit et al., Human Interleukin-3 Contains a Discontinuous Zinc Binding Domain, Biochemical and Biophysical Research Communications, Vol. 187, No. 2, pp. 859-866, (1992).											
MB			Palmitoylt Chemical M	Brown et al, Catalytically Important Domains of Rat Carnitine Palmitoyltransferase II as Determined by Site-directed Mutagenesis and Chemical Modification, The Journal of Biological Chemistry, Vol. 269, No. 29, pp. 19157-19162, (1994).											
AB			Foa et al. Cancer Pat	Foa et al., Cytokine Gene Therapy: A New Strategy for the Management of Cancer Patients, Nat Immun, 13, pp. 65-75, (1994).											
AB			Oin et al., Rates of Carbamylation of Specific Lysyl Residues in Bovine α -Crystallins, The Journal of Biological Chemistry, Vol. 267, No. 36, pp. 26128-26133, (1992).												
AB			Polvethvle	al., Chemical ene Glycol Inc pp. 1487-1491	reas	fication of Recomes its Potency in	binant In the Muri	terleuk ne Meth	cin 2 by	y coma	Model,				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw licitation if not in conformance and not considered. Include copy of this form with next communication to Appl

DATE CONSIDERED

	ATTY. DOCKET NO.8524-71226	rage 3 of 3				
FORM PTO-1449	APPLICANTS SMIT et al.					
INFORMATION DISCLOSURE STATEMENT	FILING DATE February 27, 1997	GROUP 1648				

U.S. PATENT DOCUMENTS												
EXAMINER INITIAL		DOCUMENT No.	DATE		NAME		CLASS	SUB- CLASS	FILING DATE			
	AA1		<u> </u>					L				
FOREIGN PATENT DOCUMENTS												
EXAMINER INITIAL	<u> </u>	DOCUMENT No.	NO. DATE		COUNTRY		CLASS	SUB-CLASS TRANSLA		ОИ		
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)												
AB		Veelen et with Prot	al., ²⁵² Cf ease Treat Interleuki	Plasma I ment for n-3 ¹ , Int	Desorption Mass Localizing a No ernational Journ 185 (1993).	Spectrom	netry in C	ding Do	main			
AB.		Chloropla Interacti	oteropoulos et al., Alkylation of Cysteine 89 of the γ Subunit of hloroplast Coupling Factor 1 with N-Ethylmaleimide Alters Nucleotide nteractions, The Journal of Biological Chemistry. Vol. 269, No. 31, p. 19810-19816 (1994).									
B		Newcomb e Peptide H	Newcomb et al., Effects of Chemical Modification of Anthropleurin A Peptide Heart Stimulant, pp. 539-550.									
AB	,	Neutrophi:	Andersen et al., Intact Form of Myeloperoxidase from Normal Human Neutrophils, Archives of Biochemistry and Biophysics, Vol. 214, No. 1, pp. 273-283 (1982).									
AB		Hercus et Factor An	Hercus et al., Specific Human Granulocyte-Macrophage Colony-Stimulating Factor Antagonists, PNAS 91, pp. 5838-5842 (1994).									
AB												
EXAMINER	1	guessle	- Bae	sen		Ε	ATE CONSI	DERED	1113108			
		7				in in o	onformanc	o with	MDED 600 Dr	·aw		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw licitation if not in conformance and not considered. Include copy of this form with next communication to Appl